Vortioxetine: Clinical Trials

27 trials of Vortioxetine, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

17 completed, 5 unknown, 2 withdrawn, 1 not yet recruiting. 27 Phase 4.

By phase and status

PhaseTrialsStatus
Phase 427Completed 17, Unknown 5, Withdrawn 2, Not yet recruiting 1, Recruiting 1, Terminated 1

Follow Vortioxetine: new trials by email Literature Review of Vortioxetine trials Research Report on Vortioxetine

Trials (filtered) newest first · largest first

All 27 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
RNA Editing as a Biomarker of Antidepressant Response in Unipolar and Bipolar Depression (EDIT-ANDRE)
Vortioxetine, Cariprazine (Augmentation Phase) - Unipolar Depression, Bipolar Depression
Phase 4RecruitingMayo Clinic1202026-02-172026-06-22
Vortioxetine for Depressive Symptoms and Freezing of Gait in Parkinson Disease
Vortioxetine (tablet) - Parkinson Disease, Idiopathic, Freezing of Gait
Phase 4Not yet recruitingMarianna Amboni402025-02-012025-02-06
Vortioxetine Adjunctive Treatment in Bipolar Depression
Vortioxetine, valprote - Bipolar Depression
Phase 4CompletedFirst Affiliated Hospital of Zhejiang University1312022-03-012023-09-14
MBRP + Vortioxetine VS MBRP on Preventing Relapse in Chronic MA Users
Vortioxetine - Relapse, Cognitive Impairment
Phase 4UnknownSir Run Run Shaw Hospital2202020-09-012019-11-29
Comparison of Vortioxetine and Desvenlafaxine in Adult Patients Suffering From Depression
Vortioxetine, Desvenlafaxine - Major Depressive Disorder
Phase 4CompletedH. Lundbeck A/S6052020-06-182022-02-14
Vortioxetine in Patients With Depression and Early Dementia
Vortioxetine - Major Depressive Disorder, Dementia
Phase 4CompletedH. Lundbeck A/S822020-02-282022-08-08
Open-label, Flexible-dose Study of Vortioxetine in Patients With Depression in India
Vortioxetine - Major Depressive Disorder
Phase 4CompletedH. Lundbeck A/S4002020-02-202022-03-18
Vortioxetine in Patients With Depression Coexisting With General Anxiety Disorder (GAD)
Vortioxetine - MDD, Anxiety Disorders
Phase 4CompletedH. Lundbeck A/S1002019-12-272021-04-20
Tolerability, Safety and Efficacy of Vortioxetine
Vortioxetine - Depression
Phase 4UnknownIRCCS San Raffaele Roma202019-11-202023-06-22
Vortioxetine Monotherapy for Major Depressive Disorder in Type 2 Diabetes
Vortioxetine - Type2 Diabetes, Major Depressive Disorder
Phase 4WithdrawnTodd Doyle2019-07-012022-11-29
Study With Vortioxetine on Emotional Functioning in Patients With Depression
Vortioxetine - Major Depressive Disorder
Phase 4CompletedH. Lundbeck A/S1502019-02-052020-03-24
Vortioxetine in the Elderly vs. Selective Serotonin Reuptake Inhibitors (SSRIs): a Pragmatic Assessment
Vortioxetine, Sertraline, citalopram - Major Depressive Disorder
Phase 4CompletedAzienda Ospedaliera Universitaria Integrata Verona3622019-02-012023-05-19
Pattern Separation, Brain Derived Neurotrophic Factors, and Mechanisms of Vortioxetine
Vortioxetine - Depressive Disorder, Major Depression
Phase 4TerminatedMassachusetts General Hospital22017-08-242019-10-14
Goal Achievement After a Change to Vortioxetine in Adults With Major Depressive Disorder
Vortioxetine - Major Depressive Disorder
Phase 4CompletedTakeda1232016-12-222019-07-11
Vortioxetine for Posttraumatic Stress Disorder
Placebo, Vortioxetine - Post-Traumatic Stress Disorder
Phase 4CompletedUniversity of Miami412016-12-012021-02-08
The Relationship Among Changes in Brain Network Activation in Adult Outpatients With Major Depressive Disorder
vortioxetine - Major Depressive Disorder
Phase 4CompletedRush University Medical Center312016-12-012021-10-04
Effect of Vortioxetine, Paroxetine, and Placebo on Sexual Functioning in Healthy Volunteers
Vortioxetine, Paroxetine, Placebo - Healthy Volunteers
Phase 4CompletedTakeda3612016-11-212018-09-14
Cognitive Dysfunction in MDD Patients
Vortioxetine, Escitalopram - Major Depressive Disorder
Phase 4UnknownOleg Levada1502016-10-012019-01-10
Remediation of Age-related Cognitive Decline: Vortioxetine and Cognitive Training
Vortioxetine 10 mg, Cognitive training program - Age-related Cognitive Decline
Phase 4CompletedWashington University School of Medicine1292016-08-312020-01-14
Vortioxetine for MDD, Cognition, and Systemic Inflammatory Biomarkers
Vortioxetine - Unipolar Major Depression, Stage I, II or III Breast Cancer
Phase 4WithdrawnUniversity of Miami2016-07-012016-09-30

Showing 20 of 27. Sign in to see all of them.

Conditions studied

Depressive Disorder, Major (13)  ·  Depression (10)  ·  Anxiety Disorders (2)  ·  Bipolar Disorder (2)  ·  Cognitive Dysfunction (2)  ·  Depressive Disorder (2)  ·  Diabetes Mellitus, Type 2 (2)  ·  Parkinson Disease (2)  ·  Dementia (1)  ·  Hot Flashes (1)  ·  Neurobehavioral Manifestations (1)  ·  Panic Disorder (1)  ·  Phobia, Social (1)  ·  Recurrence (1)  ·  Schizophrenia (1)

Sponsors

H. Lundbeck A/S (5)  ·  Takeda (3)  ·  Massachusetts General Hospital (2)  ·  University of Miami (2)  ·  Azienda Ospedaliera Universitaria Integrata Verona (1)  ·  First Affiliated Hospital of Zhejiang University (1)  ·  IRCCS San Raffaele Roma (1)  ·  Lundbeck Canada Inc. (1)  ·  Marianna Amboni (1)  ·  Mayo Clinic (1)  ·  Northwell Health (1)  ·  Oleg Levada (1)  ·  Rush University Medical Center (1)  ·  Sir Run Run Shaw Hospital (1)  ·  Siyan Clinical Corporation (1)

Countries

United States (13)  ·  Italy (5)  ·  Spain (4)  ·  Estonia (3)  ·  France (3)  ·  Poland (2)  ·  South Korea (2)  ·  Ukraine (2)  ·  Argentina (1)  ·  Belgium (1)  ·  Bulgaria (1)  ·  Canada (1)  ·  China (1)  ·  Czechia (1)  ·  India (1)

Top investigators

Andrew Nierenberg, M.D. (1)  ·  Aysegul Ozerdem, MD, PhD (1)  ·  Christoph U Correll, MD (1)  ·  Deniz Ceylan, MD, PhD (1)  ·  Dominique Musselman, M.D., MSCR (1)  ·  Eric Lenze, MD (1)  ·  Isela Juarez Rojop, Ph.D (1)  ·  John M Zajecka, MD (1)  ·  Li YouMing (1)  ·  Marlene P Freeman, MD (1)  ·  Michael R Liebowitz, M.D. (1)  ·  Philip Harvey, PhD (1)  ·  Pratap Chokka, M.D. (1)

Results publications

PMID 29760763, PMID 30802419, PMID 31930057, PMID 32212856, PMID 32384884, PMID 32746941, PMID 33587394, PMID 34378539, PMID 34895181, PMID 35131363, PMID 35499104, PMID 36395989, PMID 37227402, PMID 37315590, PMID 38384338, PMID 38869978, PMID 39110846, PMID 40456468, PMID 40679716

NIH funding

2018 (2), 2016 (1)